Wells Fargo & Company Begins Coverage on Ultragenyx Pharmaceutical (NASDAQ:RARE)

Analysts at Wells Fargo & Company started coverage on shares of Ultragenyx Pharmaceutical (NASDAQ:RARE – Get Free Report) in a report issued on Friday, Marketbeat reports. The brokerage set an “overweight” rating and a $72.00 price target on the biopharmaceutical company’s stock. Wells Fargo & Company‘s price objective would suggest a potential upside of 73.83% […]

Leave a Reply

Your email address will not be published.

Previous post Cipher Capital LP Cuts Position in 3M (NYSE:MMM)
Next post ZClassic (ZCL) Reaches Market Cap of $695,516.20